Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease

Kidney International

Volumn 78, Issue 2, 2010, Pages 200-206

  Van Husen, Michael ^a   Fischer, Ann Katrin ^a   Lehnhardt, Anja ^a   Klaassen, Ilka ^a   Möller, Kristina ^a   Müller Wiefel, Dirk E ^a   Kemper, Markus J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

bone; children; chronic kidney disease; pediatric nephrology; phosphate

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; VITAMIN D;

ARTICLE; BONE METABOLISM; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; PATHOGENESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROGNOSIS; RENAL OSTEODYSTROPHY; VITAMIN D METABOLISM;

ADOLESCENT; BONE AND BONES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY DISEASES; MALE;

EID: 77954244107     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.107     Document Type: Article

References (37)

1. Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007; 30: 1819-1825.
2. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
3. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1-10.
4. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
5. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409-414.
6. Bowe AE, Finnegan R, Jan de Beur SM et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001; 284: 977-981.
7. Gattineni J, Bates C, Twombley K et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297: F282-F291.
8. Jüppner H. Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 2007; 11: S3-22.
9. Perwad F, Zhang MYH, Tenenhouse HS et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583.
10. Benet-Pagè s A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14: 385-390.
11. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278: 37419-37426.
12. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285: E1-E9.
13. Araya K, Fukumoto S, Backenroth R et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005; 90: 5523-5527.
14. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117: 2684-2691.
15. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-1647.
16. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
17. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517.
18. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
19. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant 2009; 24: 4-7.
20. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant 2008; 23: 2733-2737.
21. Zoccali C. FGF-23 in dialysis patients: ready for prime time? Nephrol Dial Transplant 2009; 24: 1078-1081.
22. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
23. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256.
24. Westerberg P, Linde T, Wikström B et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3202-3207.
25. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149.
26. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19: 615-623.
27. Ferrari SL, Bonjour J, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524.
28. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549.
29. Seeherunvong W, Abitbol CL, Chandar J et al. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 2009; 154: 906-911.
30. Klaus G, Watson A, Edefonti A et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21: 151-159.
31. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178. (Pubitemid 41623344)
32. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100-105.
33. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663.
34. Anonymous (Working Group K/DOQI). K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46: S1-S121.
35. Schwartz GJ, Haycock GB, Edelmann CM et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263.
36. Hogg RJ, Furth S, Lemley KV et al. National Kidney Foundations Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111: 1416-1421.
37. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960.